IO Biotech to Participate in the 2022 BIO International Convention

Rhea-AI Summary

IO Biotech (Nasdaq: IOBT) will participate in the 2022 BIO International Convention from June 13-16 in San Diego, California. Chief Scientific Officer Muhammad Al-Hajj, Ph.D., will present a panel discussion titled "Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking" on June 13 at 1:00 pm local time. IO Biotech is focused on developing immune-modulating cancer therapies using its T-win^® technology platform, including its lead candidate, IO102-IO103, targeting IDO and PD-L1.

NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win^® technology platform, announced today that the company will be participating at the 2022 BIO International Convention, taking place June 13 – 16, 2022, at the San Diego Convention Center in San Diego, California.

The company’s chief scientific officer, Muhammad Al-Hajj, Ph.D., will also be participating in a panel discussion titled, "Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking."

Panel details are summarized below:

Track: Oncology
Presentation: Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking
Presenter: Muhammad Al-Hajj, Ph.D., IO Biotech CSO
Date and time: Monday, June 13 at 1:00 pm local time

About IO Biotech

IO Biotech is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on its T-win^® technology platform. The T-win^® platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. IO Biotech is advancing in clinical studies its lead immuno-oncology candidate, IO102-IO103, targeting IDO and PD-L1, and through clinical and preclinical development its other pipeline candidates.  IO Biotech is headquartered in Copenhagen, Denmark and has additional offices within the United States (New York, New York and Rockville, Maryland) and United Kingdom (Monmouthshire).

For further information, please visit www.iobiotech.com

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including regarding future clinical trials, are based on IO Biotech’s current assumptions and expectations of future events and trends, which affect or may affect its business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Except to the extent required by law, IO Biotech undertakes no obligation to update these statements, whether as a result of any new information, future developments or otherwise.

Company Contact:
Mai-Britt Zocca, Ph.D.
President and CEO
IO Biotech, Inc.
mz@iobiotech.com

Investor Contact:
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com

Media Contact:
Raena Mina, Ph.D.
LifeSci Communications
646-606-1438
rmina@lifescicomms.com

FAQ

What is IO Biotech's participation in the 2022 BIO International Convention?

IO Biotech will participate in the 2022 BIO International Convention from June 13-16, 2022, in San Diego, California.

Who is presenting at the BIO International Convention for IO Biotech?

Chief Scientific Officer Muhammad Al-Hajj, Ph.D., will present at the convention.

What is the topic of the panel discussion at the convention?

The panel discussion is titled "Early Scientific and Clinical Strategy for Optimizing Value Inflection in Oncology Financing and Dealmaking".

When is IO Biotech's panel discussion scheduled?

The panel discussion is scheduled for June 13 at 1:00 pm local time.

What technology does IO Biotech use for cancer therapy?

IO Biotech develops cancer therapies based on its T-win^® technology platform.

What is IO Biotech's lead immuno-oncology candidate?

The lead immuno-oncology candidate is IO102-IO103, which targets IDO and PD-L1.